|
Published by: Espicom Healthcare Intelligence
Published: May. 31, 2007 - 162 Pages
Table of Contents
- VOLUME 1
- EXECUTIVE SUMMARY
- BREAST CANCER
- THE FACTS
- PATIENT STATISTICS
- PATIENT MODEL
- THE MARKET
- GLOBAL CANCER MARKET
- THE BREAST CANCER MARKET
- CURRENT TREATMENTS
- CHEMOTHERAPY
- TARGETED THERAPY
- RESEARCH & DEVELOPMENT OF BC DRUGS
- COMPETITOR RATIO ANALYSIS - PRODUCTS
- COMPETITOR RATIO ANALYSIS - COMPANIES
- DISCONTINUATION OF DRUGS
- APPENDIX 1
- APPENDIX 2
- APPENDIX 3
- APPENDIX 4
- APPENDIX 5
- APPENDIX 6
- GLOSSARY
- BIBLIOGRAPHY
- WEBSITE REFERENCES
- ACRONYMS
- COLORECTAL CANCER
- THE FACTS
- GLOBAL CANCER MARKET
- THE CRC MARKET
- CURRENT TREATMENTS
- CHEMOTHERAPY
- IMMUNOTHERAPY
- RESEARCH & DEVELOPMENT OF CRC DRUGS
- COMPETITOR RATIO ANALYSIS - PRODUCTS
- COMPETITOR RATIO ANALYSIS - COMPANIES
- DISCONTINUATION OF DRUGS
- APPENDIX 1
- APPENDIX 2
- APPENDIX 3
- APPENDIX 4
- APPENDIX 5
- APPENDIX 6
- GLOSSARY
- BIBLIOGRAPHY
- ACRONYMS
- VOLUME 2
- NON-SMALL CELL LUNG CANCER
- 3THE FACTS
- GLOBAL CANCER MARKET
- THE NSCLC MARKET
- RESEARCH & DEVELOPMENT OF NSCLC DRUGS
- COMPETITOR RATIO ANALYSIS - PRODUCTS
- DISCONTINUATION OF NSCLC DRUGS
- APPENDIX 1
- APPENDIX 2
- APPENDIX 3
- APPENDIX 4
- APPENDIX 5
- APPENDIX 6
- BIBLIOGRAPHY
- GLOSSARY
- ACRONYMS
- PROSTATE CANCER
- THE FACTS
- GLOBAL CANCER MARKET
- COMPETITOR RATIO ANALYSIS - PRODUCTS
- DISCONTINUATION OF DRUGS
- APPENDIX 1
- APPENDIX 2
- APPENDIX 3
- APPENDIX 4
- APPENDIX 5
- APPENDIX 6
- GLOSSARY
- REFERENCES
- ACRONYMS
- RENAL CELL CARCINOMA
- THE FACTS
- THE MARKET
- COMPETITOR RATIO ANALYSIS - PRODUCTS
- DISCONTINUATION OF DRUGS
- APPENDIX 1
- APPENDIX 2
- APPENDIX 3
AbstractLung cancer affects more than 1.2 million patients a year, with around 1.1 million deaths annually and 500,000 in the US, Europe and Japan. Find out more about market developments in this chapter of Cancer Drug Discoveries.
Key questions answered include:
- The addressable NSCLC market will increase by 17% by 2012 - what are the factors driving this?
- By 2012, products yet to be launched will account for over 50% of global NSCLC drug sales. What are they, who’s developing them and when are they expected to launch?
- What are the prospects for CancerVax, Biomira, Alfacell, Transgene and others in the hotly contested NSCLC vaccine market?
- How will the newer cytotoxics such as Eloxatin (sanofi-aventis) and satraplatin (GPC Biotech/ Pharmion/Spectrum Pharmaceuticals) fare against currently available therapies?
Get Full Details About This Report >>
|
